Clarence Peeples is part of a small club in the HIV community. He is using his experiences to help fight the virus among ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Fostemsavir plus optimized background therapy was associated with improvements in immune biomarkers among HTE patients with MDR HIV infection.

Indigenous communities in Latin America say they are being excluded from the global HIV/AIDS response, leaving them without ...

A new study published in the Journal of Clinical Tuberculosis and Other Mycobacterial Diseases showed that two ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

FOLD and EDIT are in the spotlight following patent dispute settlement news and strategic updates, respectively.

Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...

Failure to stick to HIV treatment regimens can be a problem. But Williams Morales, an activist from Chile who is living with HIV, says incorporating traditional ancestral knowledge and medicines ...